arglabin + cyclophosphamide + doxorubicin

This is a combination chemotherapy regimen consisting of three agents: arglabin, cyclophosphamide, and doxorubicin. Arglabin is a farnesyl transferase inhibitor derived from Artemisia glabella that interferes with the post-translational modification (farnesylation) of Ras oncoproteins, particularly H-Ras, thereby inhibiting their oncogenic activity. Doxorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis in cancer cells. Cyclophosphamide is an alkylating agent that crosslinks DNA strands to prevent cell division. This combination has been studied primarily as neoadjuvant or adjuvant therapy for locally advanced breast cancer in Central Asia (notably Kazakhstan), aiming to improve relapse-free survival by targeting both general tumor proliferation (via cytotoxic agents) and specific oncogenic signaling pathways (via farnesyl transferase inhibition). Clinical studies suggest the addition of arglabin may reduce hematological toxicity associated with standard AC regimens and may increase disease-free survival in certain patient subgroups[2][5][6][7].

Other names

AC + arglabinarglabin plus ACarglabin plus doxorubicin and cyclophosphamide